Cipla Evaluates US Portfolio Tucks, Generic Advair Studies Progress
Executive Summary
Alongside a build-up in the US, Cipla is keeping a sharp eye on its “profitability profile” in this market and expects to rationalize products that don’t fit the bill. But it remains on track to establishing a respiratory franchise in key regulated markets, with generic Advair studies moving forward in the US.
You may also be interested in...
Sun To Trim US Manufacturing, Over 90 Jobs At Stake
Sun Pharma is consolidating its production activities in the US transferring operations out of its Cranbury site to the one in New Brunswick. Close to 100 jobs are expected to be affected.
Home Gains Buoy Cipla In Q1 But US Momentum Pivotal
A strong run on home turf lifted Cipla in Q1, but US momentum with differentiated launches is what investors are keeping a sharp eye on. A China play in the respiratory space is also on the cards for the Indian firm.
Cipla Sounds The Bugle On US Respiratory Ambition
One "sizeable" respiratory inhalation launch in the US every year, starting next year, is what Cipla is targeting as it expands its global franchise in the segment, though a filing this year for generic Advair isn't likely. The Indian firm also expects to sew up multiple biosimilar deals targeted at key emerging markets.